

Troubles plague Strides-Mylan deal

Strides Arcolab, the Bangalore-based publicly held pharmaceutical company, has said that it will be getting only \$150 million of the \$250 million which was supposed to flow into the company as part of a transaction with Mylan. Strides Arcolab, had during December 2013 completed a transaction to sell its specialties business to Mylan for up to \$1.75 billion and then had said that it had agreed to a contingent holdback of \$250 million as US FDA had issued warning letters to one of the facilities of Strides which was being transferred to Mylan.

BS REPORTER 4

FBI/Company